BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21393164)

  • 1. Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia.
    Wirden M; Soulie C; Valantin MA; Fourati S; Simon A; Lambert-Niclot S; Bonmarchand M; Clavel-Osorio C; Marcelin AG; Katlama C; Calvez V
    J Antimicrob Chemother; 2011 Apr; 66(4):709-12. PubMed ID: 21393164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia.
    Seclén E; Del Mar González M; De Mendoza C; Soriano V; Poveda E
    J Antimicrob Chemother; 2010 Jul; 65(7):1493-6. PubMed ID: 20488982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
    Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
    J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
    Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
    J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proviral DNA as a Target for HIV-1 Resistance Analysis.
    Lübke N; Di Cristanziano V; Sierra S; Knops E; Schülter E; Jensen B; Oette M; Lengauer T; Kaiser R
    Intervirology; 2015; 58(3):184-9. PubMed ID: 26139571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 proviral resistance mutations: usefulness in clinical practice.
    Kabamba-Mukadi B; Duquenne A; Henrivaux P; Musuamba F; Ruelle J; Yombi JC; Bodéus M; Vandercam B; Goubau P
    HIV Med; 2010 Sep; 11(8):483-92. PubMed ID: 20163482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
    Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
    Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA.
    Zaccarelli M; Santoro MM; Armenia D; Borghi V; Gennari W; Gori C; Forbici F; Bertoli A; Fabeni L; Giannetti A; Cicalini S; Bellagamba R; Andreoni M; Mastroianni CM; Mussini C; Ceccherini-Silberstein F; Perno CF; Antinori A
    J Clin Virol; 2016 Sep; 82():94-100. PubMed ID: 27472519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy.
    Vitone F; Gibellini D; Schiavone P; Re MC
    J Clin Virol; 2005 Jul; 33(3):194-200. PubMed ID: 15911440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy.
    Torres-Cornejo A; Benmarzouk-Hidalgo OJ; Gutiérrez-Valencia A; Pérez-Romero P; Martín-Peña R; Ruiz-Valderas R; Viciana P; Lopez-Cortes LF
    AIDS; 2014 Jan; 28(2):201-8. PubMed ID: 24361681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of a long-term discrepancy in drug-targeted genes in plasma HIV-1 RNA and PBMC HIV-1 DNA in the same patient.
    Usuku S; Noguchi Y; Sakamoto M; Adachi T; Sagara H; Sudo K; Nishizawa M; Kondo M; Tochikubo O; Imai M
    Jpn J Infect Dis; 2006 Apr; 59(2):122-5. PubMed ID: 16632914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of ARV resistance mutations and impact of genotyping test in HIV patients with advance disease in São Paulo, Brazil.
    Rodrigues R; Custódio RM; Bueno SM; Eira M; Ferreira JL; Jamal L; Duarte AJ; Brígido LF
    J Clin Virol; 2005 Apr; 32(4):336-7. PubMed ID: 15780815
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) proviral DNA in peripheral blood mononuclear cells by SYBR green real-time PCR technique.
    Gibellini D; Vitone F; Schiavone P; Ponti C; La Placa M; Re MC
    J Clin Virol; 2004 Apr; 29(4):282-9. PubMed ID: 15018857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients.
    Bon I; Gibellini D; Borderi M; Alessandrini F; Vitone F; Schiavone P; Re MC
    J Clin Virol; 2007 Apr; 38(4):313-20. PubMed ID: 17306618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinctive Drug-resistant Mutation Profiles and Interpretations of HIV-1 Proviral DNA Revealed by Deep Sequencing in Reverse Transcriptase.
    Yin QQ; Li ZP; Zhao H; Pan D; Wang Y; Xu WS; Xing H; Feng Y; Jiang SB; Shao YM; Ma LY
    Biomed Environ Sci; 2016 Apr; 29(4):239-47. PubMed ID: 27241734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
    Masciotra S; Garrido C; Youngpairoj AS; McNulty A; Zahonero N; Corral A; Heneine W; de Mendoza C; García-Lerma JG
    AIDS; 2007 Nov; 21(18):2503-11. PubMed ID: 18025887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation.
    Bonora S; Nicastri E; Calcagno A; Gonzalez de Requena D; D'Ettorre G; Sarmati L; Palmisano L; Vullo V; Di Perri G; Andreoni M
    J Med Virol; 2009 Mar; 81(3):400-5. PubMed ID: 19152404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.
    Carr JM; Cheney KM; Coolen C; Davis A; Shaw D; Ferguson W; Chang G; Higgins G; Burrell C; Li P
    J Clin Microbiol; 2007 Apr; 45(4):1288-97. PubMed ID: 17314225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.